Skip to content
doc.socialdoc.social

Listening

Episode

Morning Brief — Tuesday, November 17, 2026

Play episode— Morning Brief — Tuesday, November 17, 2026

Keeps playing through doc social Morning Brief

4 stories this morning, for surgeons and the people who support them.

  • Xtant Medical Q3 2026: revenue $24.3M (vs $33.3M; +5% sequentially from $23.0M), decline from divested Coflex/CoFix and international hardware ($5.4M) and ended wound care licensing ($5.5M); biologics $19.3M (+13% YoY, incl. $2.2M HEMOBLAST); gross margin 56.3% (vs 66.1%); net loss $3.6M; second consecutive quarter below guidance; withdraws FY26 guidance (cut Aug 11 to $99-103M from $101-105M; nine-month revenue $68.2M); board-led strategic review with no timetable; no earnings call; cash $7.8M, debt $22M, $2.1M revolver availability — Xtant 8-K Ex. 99.1, Nov 16, 2026 (also PR Newswire 302939954). Prior guidance and Companion Spine as buyer of Coflex/CoFix (Dec 2025): Q2 8-K Ex. 99.1, Aug 11, 2026, https://www.sec.gov/Archives/edgar/data/1453593/000149315226036979/ex99-1.htm. Q4 needed for low end computed: $99M - $68.2M = $30.8M. Source
  • Medtronic to acquire Contego Medical (carotid; exclusive US distribution partner since January 2025), valued at $380M with potential post-acquisition payments, expected close in Medtronic FQ3; includes Neuroguard IEP Direct (TCAR with integrated embolic protection plus flow reversal; Contego announced FDA PMA Nov 11, 2026; PERFORMANCE III 30-day: zero strokes, neuro deaths, cranial nerve injuries, MIs; MAE 0.69% ITT) and Excipio peripheral thrombectomy (complements Liberant). Competitive context: Boston Scientific closed Silk Road Medical (TCAR) Sept 17, 2024 for ~$1.126B net of cash acquired — Medtronic release, Galway, Nov 16, 2026. FDA PMA: https://evtoday.com/news/fda-approves-contegos-neuroguard-iep-direct-system-for-tcar-iep (Nov 11, 2026). Silk Road: Boston Scientific 10-Q Q3 2025, https://www.sec.gov/Archives/edgar/data/885725/000088572525000050/bsx-20250930.htm. Source
  • J Arthroplasty (online Nov 13), participant- and assessor-blinded single-center RCT, 181 primary TKA for OA randomized intraoperatively to infrapatellar fat pad excision vs minimal resection: no significant between-group difference in KOOS or OKS at 3, 12 or 24 months; both arms exceeded MCID on KOOS Pain; no KOOS improvement between 12 and 24 months; 140 analyzed at 24 months (22% loss to follow-up) — Howard et al., 'Effect of Excision of the Infrapatellar Fat Pad in Total Knee Arthroplasty: A Double-Blinded Randomized Controlled Trial', J Arthroplasty 2026 Nov 13, doi:10.1016/j.arth.2026.11.008 (PMID 43025520). UK NHS authors (Liverpool, Salford). Source
  • Two propensity-matched studies of cervical surgery at age 75+: J Neurosurg Spine (Goodman Campbell, online Nov 13) 1,155 elective ACDFs, 73 aged >=75; 69 matched pairs at parity on all PROMs through 2 years. Eur Spine J (Seoul National University Bundang Hospital registry, online Nov 16) 1,016 DCM patients, 78 matched pairs; 12-month severity-specific JOA MCID 42.3% vs 46.2% (p=0.74, equivalence not established); recorded complications 7.1% older vs 11.0% younger; rehab transfer more frequent in older patients in full cohort (15.2% vs 5.8%) — Rezner et al., J Neurosurg Spine 2026 Nov 13, doi:10.3171/2026.4.SPINE26195 (PMID 43024881); Ham et al., Eur Spine J 2026 Nov 16, doi:10.1007/s00586-026-10525-y (PMID 43037686), https://pubmed.ncbi.nlm.nih.gov/43037686/. Both conclude age alone should not preclude surgery. Source

Contribute to the Brief

Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.

Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.

Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.